Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
2022 · Nature Medicine · 260 citations
https://doi.org/10.1038/s41591-022-01971-4
S
Samvel B. Gasparyan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
48
Papers
886
Citations
13
h-index
14
i10-index
Samvel B. Gasparyan is an academic researcher from AstraZeneca (Brazil). The author has contributed to research in topics: Diabetes Treatment and Management & Statistical Methods in Clinical Trials & Heart Failure Treatment and Management. The author has an h-index of 13, co-authored 41 publications.
ORCID: 0000-0002-4797-2208Papers by this author
worksClinical trial designs to assess treatment effects on glomerular filtration rate decline
2024 · Kidney International · 9 citations
https://doi.org/10.1016/j.kint.2024.06.007
Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
2024 · Journal of the American College of Cardiology · 4 citations
https://doi.org/10.1016/j.jacc.2024.03.385
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat